By Fineline Cube 
Gan & Lee Pharmaceuticals (SHA: 603087) has announced the receipt of marketing approval for its insulin glargine cartridge in Pakistan. This approval marks another milestone in the company’s global expansion strategy.
Product Profile
Insulin glargine, a long-acting insulin analogue also known as a basal insulin analogue, is administered once daily and provides up to 24 hours of blood sugar control post-injection. The product is characterized by its long duration of action, lack of blood concentration peaks, and steady blood sugar reduction, alongside a favorable efficacy and safety profile.
Market Context
Originally developed by Sanofi under the trade name Lantus, insulin glargine is a well-established treatment in the management of diabetes. Gan & Lee’s insulin glargine (pre-filled) was previously approved in Pakistan in 2022, becoming the first generic version of Lantus in the country.-Fineline Info & Tech